A study looked at the remodelling that occurs within the TIME in response to HER2-directed treatment with trastuzumab in advanced gastric cancer, and found that there was a significant increase in the infiltration of NK cells and CD8 T-cells indicating an enhanced, “immune-hot” response following HER2-targeted treatment [71]. The gene discussed is ERBB2; the disease is gastric cancer.